APOE-targeted therapies on the horizon

Almost everything we tell carriers today works around the gene, not on it: manage lipids, blood pressure, sleep, and exercise to lower the risk APOE4 creates. The obvious next question is whether we could one day target APOE itself. One remarkable patient suggests it might be possible, and she has handed researchers a concrete blueprint. The strategies are genuinely exciting. They are also very early, with no APOE-targeting drug approved.

The patient who shouldn’t have been protected

In 2019, researchers described a woman from a large Colombian family who carried a PSEN1 mutation, a gene change that causes early-onset Alzheimer’s with near-certainty, usually in the mid-40s. She stayed cognitively healthy into her 70s, almost three decades later than expected. Her brain scans deepened the puzzle: she had enormous amyloid buildup, more than typical patients, yet relatively little tau tangling and little neurodegeneration. She made plenty of plaque, but the cascade from plaque to tangles to brain damage was somehow interrupted.

The likely reason was that she carried two copies of a rare variant, APOE3 Christchurch. The leading explanation is mechanical: this variant weakens APOE’s grip on a scaffold molecule called heparan sulfate proteoglycans, and that handhold appears to be one of the routes by which APOE drives tau pathology downstream of amyloid. Loosen the grip and you blunt the next step in the chain. That single case electrified the field, because it suggested that changing how APOE behaves could blunt the disease even after amyloid has piled up, and it handed drug developers a target to imitate. A 2025 longitudinal follow-up in Nature Medicine tracked the same protected carrier in more detail, reinforcing that her tau pathology stayed unusually confined despite the heavy amyloid load, which is the pattern any APOE-pathway drug would be trying to recreate.

A second protected patient points to the same pathway

The Christchurch woman is not a one-off. In 2023, researchers from the same Colombian kindred described a man who also carried the near-deterministic PSEN1-E280A mutation yet stayed cognitively sharp until about age 70, roughly two decades past the family’s typical mid-40s onset (Reelin-COLBOS case, Nature Medicine). His brain showed the same striking signature as the Christchurch case: a very high amyloid load (he had about 48% more plaque than typical early-dementia carriers in his family) but limited tau tangling, especially spared in the entorhinal cortex where tau usually strikes first. The protective variant was different, a gain-of-function change in a gene called RELN (Reelin), but it converges on the same downstream lever: it tamps down the abnormal phosphorylation of tau. Two unrelated rare variants, two protected people, one shared theme, which is exactly the kind of human evidence that gives drug developers confidence the pathway is real and not a fluke.

These cases are the human proof-of-concept behind the whole APOE-pathway effort. Mouse models can be argued with; a person who carried a guaranteed-dementia mutation and walked it off for decades is harder to dismiss. The honest framing is that this is an n of one or two, rare experiments of nature that point a direction. They are a reason to build drugs, not drugs themselves.

Why APOE is a tempting target

The ε4 protein differs from the common ε3 by a single amino-acid swap (an arginine where ε3 has a cysteine, at position 112), and that one tweak makes ε4 less stable and worse at its lipid-handling job. Because APOE sits so far upstream, influencing amyloid clearance, lipid transport, blood-brain-barrier integrity, and neuroinflammation, nudging how it behaves could in principle ripple through several disease pathways at once. A 2019 review in Nature Reviews Neurology laid out that logic and the menu of approaches now being explored.

The strategies being explored

Treat these as research directions, not pharmacy shelves.

• Delivering a protective form via gene therapy. Since ε2 and the Christchurch variant look protective, one approach uses a viral vector to add a protective APOE gene to the brain. Lexeo Therapeutics’ LX1001, an APOE2 gene therapy for ε4/ε4 carriers, has been through an early-phase human trial (registered as NCT03634007), the first attempt to test this idea in people.
• Gene editing. Base-editing tools that could rewrite an ε4 “letter” back to the ε3 version are being explored in the lab (including work from David Liu’s group at the Broad Institute), still preclinical.
• “Structure correctors.” Small molecules designed to change the shape of the ε4 protein so it folds and behaves more like the benign ε3 form.
• Antisense oligonucleotides (ASOs). Short genetic sequences that can dial a gene’s output up or down, raising the question of whether lowering ε4, or shifting the balance toward a helpful form, helps and where.
• Targeting APOE’s interactions, for example its binding to heparan sulfate (the Christchurch route) or to the brain’s immune cells.

The first drug built specifically for APOE4 carriers

Most of the programs above aim at APOE itself. A different bet, from Halia Therapeutics, borrows the “copy a protected person” logic but points it at the brain’s immune machinery. Their lead compound, HT-4253, is a small molecule that crosses into the brain and blocks an enzyme called LRRK2. It appears to be the first drug program designed around APOE4 carriers rather than Alzheimer’s patients in general. The 2026 write-up in npj Drug Discovery lays out the rationale.

Here is the chain. Among APOE4 carriers, some appear unusually cognitively resilient, and one thing they seem to share is a protective variant in a gene called RAB10. Think of RAB10 as a delivery truck inside the cell that helps microglia (the brain’s cleanup crew) do their job and keep the lysosome (the cell’s garbage disposal) running. LRRK2 is an enzyme sitting upstream that tags RAB10 with a phosphate group; too much of that tagging (measured as phosphorylated Rab10, or pRab10) gums up the trucks, inflames the microglia, and lets tau over-phosphorylate. HT-4253 turns down LRRK2, which lowers pRab10, dampens neuroinflammation, cuts tau phosphorylation, and restores microglial function in the lab. In effect, it tries to reproduce with a pill what the protective RAB10 carriers get from their genes.

Note how different this is from the anti-amyloid antibodies (lecanemab, donanemab) that dominate the headlines. Those drugs go after plaque directly. HT-4253 leaves amyloid alone and works on neuroinflammation and the cell’s disposal system, which is a distinct and complementary lever.

Now the sober part. The mechanistic story so far rests on preclinical cell-model work showing the drug hits its target and moves pRab10 the right way. On the human side, HT-4253 has cleared a completed Phase 1 safety trial (NCT06537817), a single- and multiple-ascending-dose study in 80 healthy volunteers, with a favorable safety profile reported. A Phase 2a biomarker study (NCT07399171) is planned but not yet recruiting: 48 weeks in cognitively normal APOE4 carriers, identified through the United Arab Emirates population-genomics program and confirmed with C2N’s PrecivityAD2 blood test. Crucially, that trial tracks blood-based biomarkers, not clinical outcomes like memory decline. So there is no efficacy data in humans yet. What exists is a plausible mechanism, target engagement in cells, and a clean early safety readout. That is a real start and a long way from proof that it protects anyone’s brain.

The honest status check

Most of this lives in cell models, animal studies, and the earliest stages of human research. No APOE-targeting drug is approved. APOE is woven deep into normal biology and does essential work, so altering it risks unintended consequences, and the brain is an unforgiving place to find them. Timelines are uncertain and measured in years, not months. Treat any breathless “cure for the APOE4 gene” headline with deep skepticism.

What to do with this today

Nothing here changes your move this week. Work the evidence-based levers you can act on now, the same ones that drive risk: lipids, blood pressure, fitness, sleep. If the science appeals to you, consider joining research, where carriers are actively sought, since that is how a future therapy gets tested at all. A program like HT-4253’s Phase 2a is exactly the kind of trial that needs cognitively normal carriers, and it will not launch without them.

Common questions

Is there a drug that fixes the APOE4 gene? No, and nothing is close to approval. The science is serious and the targets are real, but this is early-stage research, not a current treatment option.

What was the “Christchurch” discovery? A protected patient whose rare APOE variant seemed to shield her brain despite heavy Alzheimer’s pathology, which inspired efforts to recreate that protection with drugs.

Is HT-4253 different from lecanemab or donanemab? Yes. The approved anti-amyloid antibodies clear plaque. HT-4253 works on a separate lever, calming neuroinflammation and repairing the brain’s cellular disposal system by inhibiting LRRK2. It has passed an early safety trial but has no efficacy data in humans yet.

Should I wait for these instead of changing my lifestyle? No. The responsible move today is unchanged: work the levers you can act on this week, and consider a prevention trial if it appeals.

File this under cautious optimism, and do not wait for it. The pipeline is real and the science is serious, but your habits, blood pressure, and fitness are things you can act on now. This is general education, not medical advice.